REGENXBIO CEO Ken Mills Shines Light on Promising Phase I Trials for Wet AMD Gene Therapy RGX-314 - a podcast by OIS Podcast
from 2018-08-15T00:00
::
::
REGENXBIO founding CEO Ken Mills reviews the company’s recent positive Phase I results for RGX-314, a potentially game-changing gene therapy for wet AMD. Mills also shares the responsibility he feels leading a pioneer in the blockbuster gene therapy field.
Further episodes of OIS Podcast | Ophthalmology
Further podcasts by OIS Podcast
Website of OIS Podcast